Quant-based Vaxart stock price forecast models show probability-weighted targets of $0.60 (bear case) and $0.82 (bull case) over the next 6–8 weeks, factoring in sector-wide volatility trends and Nasdaq sentiment indexes. To get a sense of who is truly in control of Vaxart, Inc. ( NASDAQ:VXRT ), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's share in the company with 59% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Additionally, there’s been notable chatter about Vaxart’s progress with an oral tablet vaccine candidate for norovirus, highlighted in a recent scientific article shared on the platform. Posts on X reflect curiosity about how this could position the company in the competitive vaccine market, especially given the unique delivery method. The conversation continues to evolve as investors weigh the long-term implications of these updates. The latest chart-based Vaxart stock price forecast places emphasis on MACD turning positive, a rare occurrence amid recent downtrends, often signaling incoming momentum bursts.
